Breaking news
Imagen de una célula tumoral donde se aprecian los cambios en la morfología de las mitocondrias (en verde) tras el tratamiento con nanopartículas de óxido de hierro recubiertas con DMSA
  • Un equipo del CNB-CSIC analiza el potencial de distintos recubrimientos de estas nanopartículas como terapias inductoras de estrés oxidativo para tratar al cáncer
  • Las nanopartículas de hierro son una herramienta útil para el transporte dirigido de fármacos antitumorales, ya que minimizan los efectos secundarios

Mantener estables los niveles de estrés oxidativo es fundamental para la salud celular, si bien este equilibrio está habitualmente desregulado en células tumorales. Este desequilibro, hace que las células tumorales sean más sensibles a cambios externos que puedan aumentar el estrés de manera que sea incompatible con la supervivencia celular. Por este motivo, numerosas investigaciones actuales exploran terapias inductoras de estrés oxidativo como tratamiento del cáncer, y el campo de la nanomedicina ofrece prometedores avances. El nuevo trabajo de investigadores del Centro Nacional de Biotecnología perteneciente al Consejo Superior de Investigaciones Científicas (CNB-CSIC) en en la revista Biomaterials identifica recubrimientos de nanopartículas de óxido que afectan específicamente al crecimiento de las células tumorales al generar elevados niveles de estrés oxidativo que terminan afectando su metabolismo mitocondrial, lo que abre la posibilidad de su uso combinado en terapias ya establecidas.

Las nanopartículas de óxido de hierro son una novedosa herramienta en biomedicina: su pequeño tamaño y la capacidad de nuestro cuerpo de metabolizarlas con muy baja toxicidad hace que sean adecuadas en métodos poco invasivos para el diagnóstico y tratamiento de enfermedades como el cáncer, donde ya se habían usado para el transporte selectivo de fármacos.  

Nuria María Arribas, directora gerente de InLac; Ana Cuenda, vicedirectora del Centro Nacional de Biotecnología, Javier Maté Caballero, subdirector general de Control de la Calidad y Laboratorios Agroalimentarios del Ministerio de Agricultura Pesca y Alimentación (MAPA), en la presentación del método en Madrid.
  • Este método permitirá a los fabricantes certificar los quesos de mezcla y potenciar su valor y prestigio en los mercados nacional e internacionales

La Organización Interprofesional Láctea (InLac), Zeulab y el Centro Nacional de Biotecnología del Consejo Superior de Investigaciones Científicas (CSIC) han presentado esta semana en la Residencia de Estudiantes de Madrid el desarrollo de una técnica que permite determinar la proporción de leche de diferentes especies presente en quesos de mezcla y que podrá ser aplicada por los laboratorios de análisis del sector.

Durante la jornada de presentación han intervenido la directora gerente de InLac, Nuria María Arribas; la vicedirectora del Centro Nacional de Biotecnología, Ana Cuenda y el subdirector general de Control de la Calidad y Laboratorios Agroalimentarios del Ministerio de Agricultura Pesca y Alimentación (MAPA), Javier Maté Caballero. Mientras tanto, la presentación del método de cuantificación de leches de diferentes especies en quesos de mezcla corrió a cargo del director de Zeulab, Pedro Razquin, y Alberto Paradela del CNB-CSIC. Para finalizar hubo una mesa redonda que contó con la participaron de José Carrión (Central Quesera Montesinos), Óscar Esteban (Queserías Entrepinares), Ignacio Bernáez (Grupo Lactalis), Gema Barceló (Grupo TGT) y Manuel Viaño (Reny Picot).

Wednesday, 13 December 2023 18:00

Working together against deadly Marburg virus

Transmission electron micrograph showing filamentous virions of the Marburg virus
  • The multidisciplinary European consortium MARVAX will receive 7.4 million euros over the next four years for the research and development of vaccines against Marburg viruses.

Researchers from France, Spain and Germany will develop novel vaccine candidates, which will be tested in preclinical animal models and bring them to the stage where they are ready for phase I clinical trials. The Bernhard Nocht Institute for Tropical Medicine (BNITM, Germany) will coordinate the MARVAX consortium that also includes the Institut Pasteur (France), the National Centre for Biotechnology of the Spanish National Research Council (CNB-CSIC, Spain), and CZ Vaccines (Zendal group, Spain).

The Marburg virus is one of the most dangerous pathogens for humans. According to the World Health Organization (WHO), the mortality rate ranges between 24% and 88%, depending on the strain of the virus and the quality of the medical care. Like Ebola virus, it is an RNA virus of the filovirus family. The first cases of the Marburg virus disease were documented in 1967. Since then, there have been several outbreaks in eastern, central and southern Africa. In 2021 for the first time the virus emerged in West Africa and this year in Tanzania and Equatorial Guinea. Marburg virus disease is a zoonosis as the initial transmission usually comes from animals: the natural hosts of this virus are presumably fruit bats. Marburg virus is transmitted between humans through body fluids, possibly also through semen.

Pilar Cubas, new president of the Biosciences and Biotechnology area of the State Research Agency

Pilar Cubas has been appointed president of the Biosciences and Biotechnology (BIO) thematic area of the State Research Agency. This appointment has an initial duration of three years during which Cubas will be responsible for leading the tasks assigned to the Biosciences and Biotechnology area, which in turn contains three sub-areas: Integrative Biology and Physiology, Molecular and Cellular Biology and Biotechnology.

Pilar Cubas holds a PhD in Biological Sciences from the Autonomous University of Madrid. Her career began in the field of the development of the nervous system of Drosophila melanogaster, and as a postdoctoral researcher her interests turned towards the molecular genetics of plants. In Rico Coen's laboratory at the John Innes Institute (Norwich, UK), she discovered the TCP domain, typical of a family of plant transcription factors. She also studied the role of the CYLOIDEA gene in the evolution of bilateral floral symmetry and discovered the molecular basis responsible for the change in the symmetry of the flowers of a natural variant of Linaria vulgaris, first described by Linnaeus.

Researcher at the CNB-CSIC since 2002, her group studies the function of TCP genes in the control of plant architecture and the genetic networks involved in this process in Arabidopsis thaliana. She has also studied the evolution of BRANCHED1 genes in other angiosperms, particularly in Solanaceae. Cubas collaborates with leading international groups in the study of branching control and signalling by strigolactones. Her research is reflected in the publication of more than 60 scientific articles in specialised journals, she has obtained international cooperation funds and maintains contracts and collaborations with companies.

In addition to Cubas, other CNB-CSIC researchers collaborate in the AEI evaluation panels: Inés M Antón in the area of Biosciences and Biotechnology, Andrea Chini in the area of Agricultural and Agrifood Sciences and Susanna Manrubia in the area of Physical Sciences.

La Fundación ”la Caixa” impulsa la investigación en biomedicina y salud en el CNB-CSIC
  • Dos grupos del CNB entre los nuevos proyectos de investigación financiados en la sexta edición de la convocatoria CaixaResearch de Investigación en Salud, promovida por la Fundación ”la Caixa”
  • La convocatoria apoya proyectos de investigación básica, clínica o traslacional de excelencia científica y de impacto social en los ámbitos de estudio de las enfermedades cardiovasculares y las infecciosas, en oncología y en neurociencias, así como proyectos que desarrollan tecnologías facilitadoras en estos ámbitos.

La Fundación ”la Caixa” ha celebrado en Barcelona el acto de entrega de ayudas a los 33 proyectos de investigación en biomedicina y salud que se llevarán a cabo en centros de España y Portugal. Se trata de proyectos seleccionados en el marco de la convocatoria CaixaResearch de Investigación en Salud 2023, que tiene el objetivo de impulsar la investigación biomédica de excelencia con gran impacto social en investigación básica, clínica y traslacional. Los grupos de Daniel López Serrano y José María Valpuesta se encuentran entre los seleccionados para desarrollar estos proyectos.

En la ceremonia, que ha tenido lugar en el Museo de la Ciencia CosmoCaixa, el director general de la Fundación ”la Caixa”, Antonio Vila Bertrán, ha recordado: «La investigación científica es fundamental para el progreso social y el bienestar de los ciudadanos. La ciencia no solo nos ayuda a construir la sociedad del conocimiento, sino que es clave para mejorar la calidad de vida de aquellos que más lo necesitan».

La convocatoria, a la que este año se habían presentado 493 propuestas, está especialmente dirigida al abordaje de retos de salud, como las enfermedades infecciosas (ámbito sobre el que se han elegido 8 proyectos), las neurociencias (7), las enfermedades cardiovasculares y metabólicas relacionadas (7) y la oncología (6). Además, otras 5 iniciativas premiadas desarrollarán tecnologías facilitadoras en alguno de estos campos.

NOTE! This site uses cookies and similar technologies.

If you continue browsing or do not change browser settings, we consider your acepptance for using. Learn more

I understand

COOKIES POLICY

A cookie is a text file that is stored on your computer or mobile device via a web server and only that server will be able to retrieve or read the contents of the cookie and allow the Web site remember browser preferences and navigate efficiently. Cookies make the interaction between the user and the website faster and easier.

General information

This Website uses cookies. Cookies are small text files generated by the web pages you visit, which contain the session data that can be useful later in the website. In this way this Web remembers information about your visit, which can facilitate your next visit and make the website more useful.

How do cookies?

Cookies can only store text, usually always anonymous and encrypted. No personal information is ever stored in a cookie, or can be associated with identified or identifiable person.

The data allow this website to keep your information between the pages, and also to discuss how to interact with the website. Cookies are safe because they can only store information that is put there by the browser, which is information the user entered in the browser or included in the page request. You can not run the code and can not be used to access your computer. If a website encrypts cookie data, only the website can read the information.

What types of cookies used?

The cookies used by this website can be distinguished by the following criteria:

1. Types of cookies as the entity that manages:

Depending on who the entity operating the computer or domain where cookies are sent and treat the data obtained, we can distinguish:

- Own cookies: are those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which provides the service requested by the user.

- Third party cookies: these are those that are sent to the user's terminal equipment from a machine or domain that is not managed by the publisher, but by another entity data is obtained through cookies.

In the event that the cookies are installed from a computer or domain managed by the editor itself but the information collected by these is managed by a third party can not be considered as party cookies.

2. Types of cookies as the length of time that remain active:

Depending on the length of time that remain active in the terminal equipment can be distinguished:

- Session cookies: cookies are a type designed to collect and store data while the user accesses a web page. Are usually used to store information that only worth preserving for the service requested by the user at any one time (eg a list of products purchased).

- Persistent cookies: cookies are a type of data which are stored in the terminal and can be accessed and treated for a period defined by the head of the cookie, and can range from a few minutes to several years.

3. Cookies types according to their purpose:

Depending on the purpose for which the data are processed through cookies, we can distinguish between:

- Technical cookies: these are those that allow the user to navigate through a web page or application platform and the use of different options or services it exist as, for example, control traffic and data communication, identify the session, access to restricted access parts, remember the elements of an order, make the buying process an order, make an application for registration or participation in an event, use security features while browsing store content for dissemination videos or sound or share content via social networks.

- Customization cookies: these are those that allow the user to access the service with some general characteristics based on a predefined set of criteria in the user terminal would eg language, the type of browser through which you access the service, the locale from which you access the service, etc.

- Analysis cookies: they are those that allow the responsible for them, monitoring and analyzing the behavior of users of the web sites that are linked. The information gathered through such cookies are used in measuring the activity of web sites, application or platform and for the profiling of user navigation of such sites, applications and platforms, in order to make improvements function data analysis how users use the service.

Management tool cookies

This Website uses Google Analytics.

Google Analytics is a free tool from Google that primarily allows website owners know how users interact with your website. Also, enable cookies in the domain of the site in which you are and uses a set of cookies called "__utma" and "__utmz" to collect information anonymously and reporting of website trends without identifying individual users..

For statistics of use of this website use cookies in order to know the level of recurrence of our visitors and more interesting content. This way we can concentrate our efforts on improving the most visited areas and make the user more easily find what they are looking for. On this site you can use the information from your visit for statistical evaluations and calculations anonymous data and to ensure the continuity of service or to make improvements to their websites. For more details, see the link below privacy policy [http://www.google.com/intl/en/policies/privacy/]

How to manage cookies on your computer: disabling and deleting cookies

All Internet browsers allow you to limit the behavior of a cookie or disable cookies within settings or browser settings. The steps for doing so are different for each browser, you can find instructions in the help menu of your browser.

If you decline the use of cookies, since it is possible thanks to the preferences menu of your browser or settings, reject, this website will continue to function properly without the use of the same.

Can you allow, block or delete cookies installed on your computer by setting your browser options installed on your computer:

- For more information about Internet Explorer click here.
- For more information on Chrome click here.
- For more information about Safari click here.
- For more information about Firefox click here.

Through your browser, you can also view the cookies that are on your computer, and delete them as you see fit. Cookies are text files, you can open and read the contents. The data within them is almost always encrypted with a numeric key corresponding to an Internet session so often has no meaning beyond the website who wrote it.

Informed consent

The use of this website on the other hand, implies that you paid your specific consent to the use of cookies, on the terms and conditions provided in this Cookies Policy, without prejudice to the measures of deactivation and removal of cookies that you can take, and mentioned in the previous section.